VCIM
Velan Capital Investment Management Portfolio holdings
AUM
$99.9M
This Quarter Return
+21.66%
1 Year Return
+37.46%
3 Year Return
+659.14%
5 Year Return
–
10 Year Return
–
AUM
$141M
AUM Growth
+$141M
(+15%)
Cap. Flow
-$114M
Cap. Flow
% of AUM
-80.42%
Top 10 Holdings %
Top 10 Hldgs %
89.02%
Holding
34
New
5
Increased
3
Reduced
2
Closed
13
Top Buys
| 1 |
Tourmaline Bio
TRML
|
$8.35M |
| 2 |
Roivant Sciences
ROIV
|
$5.62M |
| 3 |
Aclaris Therapeutics
ACRS
|
$1.85M |
| 4 |
ADMA Biologics
ADMA
|
$1.81M |
| 5 |
Immunovant
IMVT
|
$1.16M |
Top Sells
| 1 |
Praxis Precision Medicines
PRAX
|
$108M |
| 2 |
QIPT
Quipt Home Medical
QIPT
|
$5.6M |
| 3 |
TELA Bio
TELA
|
$4.43M |
| 4 |
MoonLake Immunotherapeutics
MLTX
|
$3.15M |
| 5 |
Gossamer Bio
GOSS
|
$2.55M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Tenet Healthcare
THC
$16.3B
| – | – |
-24,937
| Closed | -$1.64M |
|
|
ASLN
27
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
| – | – |
-625,000
| Closed | -$1.18M |
|
|
ICVX
28
DELISTED
Icosavax, Inc. Common Stock
ICVX
| – | – |
-160,630
| Closed | -$1.24M |
|
|
INBX
29
DELISTED
Inhibrx, Inc. Common Stock
INBX
| – | – |
-25,000
| Closed | -$459K |
|
30
Annexon
ANNX
$226M
| – | – |
-459,746
| Closed | -$1.09M |
|
31
Cabaletta Bio
CABA
$133M
| – | – |
-150,000
| Closed | -$2.28M |
|
32
Cullinan Oncology
CGEM
$445M
| – | – |
-75,000
| Closed | -$679K |
|
33
Edesa Biotech
EDSA
$16.3M
| – | – |
-1,281,615
| Closed | -$810K |
|
|
34
Gossamer Bio
GOSS
$562M
| – | – |
-3,065,136
| Closed | -$2.55M |
|